IRON ▼ -0.1% - Disc Medicine, Inc. $IRON - Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting Disc Medicine shares fell 0.1% following the company's presentation of initial Phase 2 trial results for its polycythemia vera treatment at the SOHO Annual Meeting. The minimal decline suggests investors are still digesting the data, with the market awaiting additional detail on efficacy and safety metrics from the RESTORE-PV trial. 09-SEP-2026 07:25 PM ET